EUVIMEDEUVIMED entdecken
Crossref

Downregulation of AP1S1 causes the lysosomal degradation of EGFR in non‐small cell lung cancer

Jangho Jeong, Ye Eun Hwang, Minwoo Lee, Seula Keum, Seongeun Song, Jung-Woong Kim, Jee-Hye Choi, Sangmyung Rhee iD

Journal of Cellular Physiology · 2023

DOI: 10.1002/jcp.31112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Physiology, 2023. Verfasst von Jangho Jeong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Chung-Ang University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: ErbB Receptors, Carcinoma, Non-Small-Cell Lung, Lysosomes, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Research Foundation of Korea, Chung-Ang University Graduate Research Scholarship, Korea Environment Industry & Technology Institute (KEITI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Matrix stiffness has been shown to play a critical role in cancer progression by influencing various cellular processes, including epidermal growth factor (EGF) signaling. However, the underlying molecular mechanisms are not fully understood. Here, we investigated the role of adaptor‐related protein complex 1 subunit sigma 1 (AP1S1), a component of adaptor protein complex‐1, in the regulation of EGF receptor (EGFR) intracellular trafficking during cancer cell progression. We found that AP1S1 expression was upregulated under stiff matrix conditions, resulting in the regulation of EGFR trafficking in non‐small cell lung adenocarcinoma cells. Knockout of AP1S1 caused the lysosomal degradation of EGFR, leading to suppressed EGF‐induced anaplastic lymphoma receptor tyrosine kinase phosphorylation. In addition, the downregulation of AP1S1 increased the sensitivity of H1975 cancer cells, which are resistant to tyrosine kinase inhibitors, to erlotinib. Collectively, our results suggest that AP1S1 could regulate EGFR recycling under stiff matrix conditions, and AP1S1 inhibition could be a novel strategy for treating cancer cells resistant to EGFR‐targeted anticancer drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsCarcinoma, Non-Small-Cell LungLysosomesLung NeoplasmsHumansCell Line, TumorDown-RegulationGene Expression Regulation, NeoplasticPhosphorylationDrug Resistance, NeoplasmProteolysisSignal TransductionProtein Kinase InhibitorsErlotinib HydrochlorideProtein Transport

Stichwörter der Autor:innen

adaptor-related protein complex 1 subunit sigma 1epidermal growth factor receptorlung adenocarcinomamatrix stiffnesstyrosine kinase inhibitor resistance

Substanzen

ErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsErlotinib Hydrochloride

Autor:innen und Institutionen

  • Department of Life Science, Chung-Ang University, Seoul, Republic of Korea.

ORCID-Profile: Sangmyung Rhee

Förderung

  • National Research Foundation of Korea
  • Chung-Ang University Graduate Research Scholarship
  • Korea Environment Industry & Technology Institute (KEITI)

Zitieren

APA

Jeong, J., Hwang, Y. E., Lee, M., Keum, S., Song, S., Kim, J. W., Choi, J. H., & Rhee, S. (2023). Downregulation of AP1S1 causes the lysosomal degradation of EGFR in non‐small cell lung cancer. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.31112

Vancouver

Jeong J, Hwang YE, Lee M, Keum S, Song S, Kim JW, et al. Downregulation of AP1S1 causes the lysosomal degradation of EGFR in non‐small cell lung cancer. Journal of Cellular Physiology. 2023. doi:10.1002/jcp.31112

BibTeX
@article{Jeong2023,
  author = {Jeong, Jangho and Hwang, Ye Eun and Lee, Minwoo and Keum, Seula and Song, Seongeun and Kim, Jung-Woong and Choi, Jee-Hye and Rhee, Sangmyung},
  title = {Downregulation of AP1S1 causes the lysosomal degradation of EGFR in non‐small cell lung cancer},
  journal = {Journal of Cellular Physiology},
  year = {2023},
  doi = {10.1002/jcp.31112}
}
Kostenlos starten →